Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Pregnancy hormone hCG may hold clues to bone and gland health

NCT ID NCT07824102

Knowledge-focused Sponsor: Martin Blomberg Jensen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 17, 2026 · Last updated Sep 18, 2026 · Updated 1 time

Summary

Researchers are studying whether blood levels of luteinizing hormone (LH) and human chorionic gonadotropin (hCG) are linked to the presence, severity, and long-term outcomes of endocrine disorders such as osteoporosis, thyroid disease, and adrenal gland problems. The study enrolls about 20,000 adults aged 18 to 90 who are referred to or followed at a hospital endocrinology department. Participants give blood samples for hormone and biomarker analysis, and researchers track their health through national registries to see how hormone levels relate to future diagnoses and fractures.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If researchers find a clear link between these hormones and endocrine disease, doctors could one day use a simple blood test to spot bone, thyroid, or adrenal problems earlier.
What could go wrong
This is an observational study, so it can only show associations, not cause and effect. A link between hormone levels and disease may not hold up in other patient groups or lead to any change in care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 20,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Dec 2045

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

All patients referred or followed at the Department of Endocrinology and Internal Medicine, Herlev Hospital for suspected or confirmed: Osteoporosis, Hypercalcemia/PHPT, thyroid disease, adrenal disease, pituitary disease.

Ages

18 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients referred to or patients actively followed at the Department of Endocrinology and Internal Medicine at Herlev Hospital * Age 18-90 Exclusion Criteria: * Lacking mental capacity to provide informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Adrenal gland disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

adrenal gland disorder hypercalcemia disease osteoporosis pituitary gland disorder primary hyperparathyroidism thyroid gland disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Adrenal gland disease Hypercalcemia Osteoporosis Pituitary disease Primary hyperparathyroidism Thyroid diseases

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Department of Endocrinology and Internal Medicine, Herlev Hospital

    RECRUITING

    Herlev, 2730, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.